Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space – an emerging area in cancer immunology. The seller will retain the Northern Biologics name and will continue to drive certain preclinical efforts on one of the programs, while Boehringer Ingelheim will be responsible for clinical, regulatory and commercial development of the acquired programs. Northern Biologics Inc is a sister company of our client, Mosaic Biomedicals. Read the full story here